In Silico Design and ADMET Profiling of Thiadiazole Derivatives Targeting NUDT5 (5NQR) for Breast Cancer Therapy
Biosciences Biotechnology Research Asia · 26.06.2026 · 2 (23) · 802
DOI: 10.13005/bbra/3540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosciences Biotechnology Research Asia, online erschienen am 25.06.2026. Verfasst von Vaishnavi Babasaheb Bagale und 5 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The present investigation focuses on the in-silico evaluation of thiadiazole-based substituted derivatives as potential inhibitors of the 5NQR protein, NUDT5, a promising molecular target associated with breast cancer progression. NUDT5 is involved in nuclear ATP synthesis, chromatin remodelling, and hormone-regulated breast cancer growth, making it an attractive target for anticancer drug discovery. A library of designed compounds (VB1–VB12) was subjected to molecular docking studies to evaluate their binding affinity and interactions within the active site of the target protein. Docking analysis revealed favorable ligand–protein interactions, with binding energies ranging from −8.6 to −10.5 kcal/mol. Among the tested compounds, VB11, VB1, and VB10 exhibited the strongest binding affinities, supported by multiple hydrogen bonds, hydrophobic interactions, and electrostatic interactions with key active-site amino acid residues. Lead compound selection was based on an integrated evaluation of docking affinity, ADMET properties, drug-likeness, and pharmacokinetic suitability rather than docking score alone. Although VB11 and VB1 demonstrated superior docking scores, compounds VB8, VB2, and VB7 showed more favorable overall pharmacokinetic and drug-likeness characteristics, including lower rule violations, improved predicted gastrointestinal absorption, safer CYP inhibition profiles, and balanced physicochemical properties. Physicochemical and drug-likeness analyses indicated that most compounds complied with standard medicinal chemistry parameters, supporting their suitability for further drug development. Based on the combined findings from molecular docking, pharmacokinetic profiling, and drug-likeness evaluation, VB8, VB2, and VB7 were identified as the most promising lead candidates. In this study suggests that thiadiazole derivatives may serve as valuable scaffolds for the development of novel anticancer agents targeting NUDT5 and warrants further in-vitro and in-vivo investigations.
Zitieren
APA
Bagale, V. B., Bhor, R. J., Shirode, A. M., Jadhav, P. B., Lokhande, R. R., & Mantode, P. J. (2026). In Silico Design and ADMET Profiling of Thiadiazole Derivatives Targeting NUDT5 (5NQR) for Breast Cancer Therapy. Biosciences Biotechnology Research Asia, 2(23), 802. https://doi.org/10.13005/bbra/3540
Vancouver
Bagale VB, Bhor RJ, Shirode AM, Jadhav PB, Lokhande RR, Mantode PJ. In Silico Design and ADMET Profiling of Thiadiazole Derivatives Targeting NUDT5 (5NQR) for Breast Cancer Therapy. Biosciences Biotechnology Research Asia. 2026;2(23):802. doi:10.13005/bbra/3540
BibTeX
@article{Bagale2026,
author = {Bagale, Vaishnavi Babasaheb and Bhor, Rohit Jaysing and Shirode, Amol Mohan and Jadhav, Pravin Bapurao and Lokhande, Rutuja Rajendra and Mantode, Prasad Jagdish},
title = {In Silico Design and ADMET Profiling of Thiadiazole Derivatives Targeting NUDT5 (5NQR) for Breast Cancer Therapy},
journal = {Biosciences Biotechnology Research Asia},
year = {2026},
volume = {2},
number = {23},
pages = {802},
doi = {10.13005/bbra/3540}
}
EUVIMED